Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.

Kim MH, Seong JB, Huh JW, Bae YC, Lee HS, Lee DS.

Redox Biol. 2019 Sep 3;28:101315. doi: 10.1016/j.redox.2019.101315. [Epub ahead of print]

2.

Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in obese mouse models induced by a high-fat diet.

Kim MH, Park SJ, Kim JH, Seong JB, Kim KM, Woo HA, Lee DS.

Free Radic Biol Med. 2018 Aug 1;123:27-38. doi: 10.1016/j.freeradbiomed.2018.05.061. Epub 2018 May 16.

PMID:
29777756
3.

Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.

Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, Kim CE, Park KI, Kim SC, Kim YW.

Chem Biol Interact. 2018 Jun 1;289:68-74. doi: 10.1016/j.cbi.2018.04.023. Epub 2018 Apr 24.

PMID:
29702089
4.

Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway.

Quan HY, Kim DY, Kim SJ, Jo HK, Kim GW, Chung SH.

Biochem Pharmacol. 2013 May 1;85(9):1330-40. doi: 10.1016/j.bcp.2013.02.007. Epub 2013 Feb 19.

PMID:
23435355
5.

The role of hepassocin in the development of non-alcoholic fatty liver disease.

Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL, Chang CJ.

J Hepatol. 2013 Nov;59(5):1065-72. doi: 10.1016/j.jhep.2013.06.004. Epub 2013 Jun 18. Erratum in: J Hepatol. 2017 Feb;66(2):468.

PMID:
23792031
6.

Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.

Lee MR, Yang HJ, Park KI, Ma JY.

Phytomedicine. 2019 Mar 1;55:14-22. doi: 10.1016/j.phymed.2018.07.008. Epub 2018 Jul 18.

PMID:
30668424
7.

Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.

Kang OH, Kim SB, Mun SH, Seo YS, Hwang HC, Lee YM, Lee HS, Kang DG, Kwon DY.

Int J Mol Med. 2015 Mar;35(3):803-9. doi: 10.3892/ijmm.2015.2074. Epub 2015 Jan 21.

PMID:
25605057
8.

S-allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway.

Hwang YP, Kim HG, Choi JH, Do MT, Chung YC, Jeong TC, Jeong HG.

J Nutr Biochem. 2013 Aug;24(8):1469-78. doi: 10.1016/j.jnutbio.2012.12.006. Epub 2013 Mar 1.

PMID:
23465592
9.

Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.

Jin SH, Yang JH, Shin BY, Seo K, Shin SM, Cho IJ, Ki SH.

Toxicol Appl Pharmacol. 2013 Aug 15;271(1):95-105. doi: 10.1016/j.taap.2013.04.023. Epub 2013 May 5.

PMID:
23651738
10.

Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.

Castaño D, Larequi E, Belza I, Astudillo AM, Martínez-Ansó E, Balsinde J, Argemi J, Aragon T, Moreno-Aliaga MJ, Muntane J, Prieto J, Bustos M.

J Hepatol. 2014 May;60(5):1017-25. doi: 10.1016/j.jhep.2013.12.012. Epub 2013 Dec 19.

PMID:
24362075
11.

Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.

Seo MS, Kim JH, Kim HJ, Chang KC, Park SW.

Toxicol Appl Pharmacol. 2015 Apr 15;284(2):113-24. doi: 10.1016/j.taap.2015.02.020. Epub 2015 Feb 28.

PMID:
25737164
12.

Non-Alcoholic Fatty Liver Disease.

Engin A.

Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19. Review.

PMID:
28585211
13.

Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.

Huang H, Lee SH, Sousa-Lima I, Kim SS, Hwang WM, Dagon Y, Yang WM, Cho S, Kang MC, Seo JA, Shibata M, Cho H, Belew GD, Bhin J, Desai BN, Ryu MJ, Shong M, Li P, Meng H, Chung BH, Hwang D, Kim MS, Park KS, Macedo MP, White M, Jones J, Kim YB.

J Clin Invest. 2018 Dec 3;128(12):5335-5350. doi: 10.1172/JCI63562. Epub 2018 Oct 29.

14.
15.

Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.

Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY, Xin HB.

Lipids Health Dis. 2017 Apr 27;16(1):82. doi: 10.1186/s12944-017-0464-z.

16.

Ping-tang Recipe () improves insulin resistance and attenuates hepatic steatosis in high-fat diet-induced obese rats.

Yang SY, Zhao NJ, Li XJ, Zhang HJ, Chen KJ, Li CD.

Chin J Integr Med. 2012 Apr;18(4):262-8. doi: 10.1007/s11655-012-1023-0. Epub 2012 Mar 30.

PMID:
22457136
17.

Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease.

Kim S, Hong J, Jeon R, Kim HS.

Nutr Res. 2016 Jan;36(1):90-100. doi: 10.1016/j.nutres.2015.11.002. Epub 2015 Nov 10.

PMID:
26773785
18.

Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.

Zhang Y, Geng C, Liu X, Li M, Gao M, Liu X, Fang F, Chang Y.

Mol Metab. 2016 Nov 17;6(1):138-147. doi: 10.1016/j.molmet.2016.11.002. eCollection 2017 Jan.

19.

Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.

Patel TP, Rawal K, Soni S, Gupta S.

Biomed Pharmacother. 2016 Oct;83:785-791. doi: 10.1016/j.biopha.2016.07.028. Epub 2016 Aug 1.

PMID:
27490779
20.

Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.

Su H, Li Y, Hu D, Xie L, Ke H, Zheng X, Chen W.

Free Radic Biol Med. 2018 Oct;126:269-286. doi: 10.1016/j.freeradbiomed.2018.08.024. Epub 2018 Aug 22.

PMID:
30142454

Supplemental Content

Support Center